FindTrial
Sign In

A prospective cohort study of evaluation of minimal residual disease in acute myeloid leukemia by multi-indicator combination

A prospective cohort study of evaluation of minimal residual disease in acute myeloid leukemia by multi-indicator combination

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061148
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

Gold Standard:Morphology, immunology, cytogenetic and molecular methods
Index test:LAIP,&#32
leukemia-associated&#32
mutation&#32
and&#32
fusion&#32
genes,overexpressed&#32
gene&#32
including&#32
WT1,&#32
OGM

Sponsors

Peking University People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. All AML patients diagnosed in Peking University Peoples Hospital and received chemotherapy and allo-HSCT; 2. Between 6 and 60 years old; 3. Subjects are able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with APL; 2. Can't receive inductive chemotherapy; 3. Subjects who cannot comply with the study.

Design outcomes

Primary

MeasureTime frame
hematological relapse;—

Secondary

MeasureTime frame
LFS;OS;NRM;GVHD;—

Countries

CHINA

Contacts

Public ContactXiaosu Zhao
zhao.xiaosu@outlook.com+86 13501222226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026